124 related articles for article (PubMed ID: 7513937)
1. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
Iguchi H; Ikeuchi T; Kai Y; Yoshida H
Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
[TBL] [Abstract][Full Text] [Related]
2. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
Umeda K
Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
[TBL] [Abstract][Full Text] [Related]
3. [Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels].
Yasukawa A; Nihira H; Matsuki S; Fujii M; Fujiwara H; Kitano T; Kodama M; Ukai R; Tado O; Sagami K
Hinyokika Kiyo; 1984 Apr; 30(4):537-43. PubMed ID: 6207714
[TBL] [Abstract][Full Text] [Related]
4. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
Kanimoto Y; Okada K
Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
[TBL] [Abstract][Full Text] [Related]
5. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
6. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
[TBL] [Abstract][Full Text] [Related]
7. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography].
Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H
Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination].
Kumamoto Y; Tsukamoto T; Takagi Y; Furuya S; Yokoyama E; Takatsuka K; Tamiya T; Miyamoto S; Aoyama T; Honma A
Hinyokika Kiyo; 1987 Nov; 33(11):1921-41. PubMed ID: 2451412
[TBL] [Abstract][Full Text] [Related]
9. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
[TBL] [Abstract][Full Text] [Related]
10. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of anti-androgen therapy for benign prostatic hypertrophy by using transrectal prostatic ultrasonography].
Kazama T; Mizuno I; Takamine T; Umeda K; Terada T; Ishikawa S; Fuse H; Katayama T
Hinyokika Kiyo; 1990 Dec; 36(12):1423-7. PubMed ID: 1706136
[TBL] [Abstract][Full Text] [Related]
12. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
Katayama T; Umeda K; Kazama T
Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
[TBL] [Abstract][Full Text] [Related]
14. [Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method].
Shida K; Koyanagi T; Kawakura K; Nishida T; Kumamoto Y; Orikasa S; Sato S; Takeda M; Yamanaka H; Shimazaki J
Hinyokika Kiyo; 1986 Apr; 32(4):625-48. PubMed ID: 2426932
[TBL] [Abstract][Full Text] [Related]
15. [Antiandrogen therapy of benign prostatic hypertrophy: clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement].
Tsuji Y; Ariyoshi A; Nakamura H; Michinaga S; Tomita Y; Ohmori A; Tahara H; Yamashita Y; Fujisawa Y; Kajiwara I
Hinyokika Kiyo; 1992 Aug; 38(8):961-6. PubMed ID: 1384295
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy].
Kogawa T; Yanagiya H; Takashima T; Higashino I; Kudo T; Suzuki T; Mikuni T; Kido K; Tsukui A; Yagihashi Y
Hinyokika Kiyo; 1993 Mar; 39(3):281-7. PubMed ID: 7685143
[TBL] [Abstract][Full Text] [Related]
17. [Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy--with reference to estimation of size and weight of prostate by means of transrectal ultrasonotomography].
Yoshida H; Haraguchi C; Ogawa Y; Kawai N; Ohyama M; Higaki Y; Saitoh T; Imamura K
Hinyokika Kiyo; 1983 Nov; 29(11):1419-26. PubMed ID: 6203377
[TBL] [Abstract][Full Text] [Related]
18. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
19. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
20. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
